Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Agenus Inc. clinical trials
Also known as Antigenics.
The registry lists 41 studies whose lead sponsor is Agenus Inc. or one of 2 companies grouped under it. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.
Keep track of what changes. Save the Agenus Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Agenus Inc..
- Agenus Inc.31 studiesSame company
Something wrong?
- Aronex Pharmaceuticals6 studies →Acquired — became part of Agenus Inc., Jul 12, 2001 · source ↗
Something wrong?
- 4 studies →
Focus areas
Conditions Agenus Inc. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 41 of 41.
- A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory FailureRecruitingNCT07615010Phase 2
Sponsor listed in the registry: MiNK Therapeutics · First submitted after MiNK Therapeutics left Agenus Inc.
- Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory ApprovalAvailableNCT06751524
- Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)AvailableNCT05572970
- A Study of Botensilimab (AGEN1181) for the Treatment of Advanced MelanomaTerminatedNCT05529316Phase 2
- A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)CompletedNCT03495882Phase 1/2
- A Study of Botensilimab in Participants With Metastatic Pancreatic CancerCompletedNCT05630183Phase 2
- Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerActive, not recruitingNCT03860272Phase 1
- RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical CancerTerminatedNCT03894215Phase 2
- A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDSCompletedNCT04582201Phase 1
Sponsor listed in the registry: MiNK Therapeutics · First submitted before MiNK Therapeutics left Agenus Inc.
- A Study Investigating AGEN1777 in Participants With Advanced Solid TumorsCompletedNCT05025085Phase 1
- A Study of Botensilimab and Balstilimab for the Treatment of Colorectal CancerActive, not recruitingNCT05608044Phase 2
- A Study of AGEN2034 in Advanced Tumors and Cervical CancerCompletedNCT03104699Phase 1/2
- Study of AGEN1571 in Participants With Advanced Solid TumorsCompletedNCT05377528Phase 1
- AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent TherapyCompletedNCT02694822Phase 1/2
- Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced CancerCompletedNCT04121676Phase 1
- A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid TumorsCompletedNCT05108623Phase 1
Sponsor listed in the registry: MiNK Therapeutics · First submitted before MiNK Therapeutics left Agenus Inc.
- A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical CancerWithdrawnNCT05033132Phase 2
- A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent LymphomaCompletedNCT00081809Phase 2
- agenT-797 in Participants With Relapsed/Refractory Multiple MyelomaCompletedNCT04754100Phase 1
Sponsor listed in the registry: MiNK Therapeutics · First submitted before MiNK Therapeutics left Agenus Inc.
- Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)WithdrawnNCT04943627Phase 3
- A Study in Subjects With Advanced Solid TumorsTerminatedNCT04156100Phase 1
- AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable AngiosarcomaWithdrawnNCT04607200Phase 2
- Phase 1a Study to Evaluate Immunogenicity of ASV®CompletedNCT03673020Phase 1
- Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital HerpesCompletedNCT01687595Phase 2
- Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of RecurrenceTerminatedNCT01147536Phase 2
- Study of AGEN1884 With Pembrolizumab in 1L NSCLCTerminatedNCT03411473Phase 2
- Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced CancerTerminatedNCT02992977Phase 1
- Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic CancerCompletedNCT00002742Phase 3
Sponsor listed in the registry: Aronex Pharmaceuticals · First submitted before Aronex Pharmaceuticals became part of Agenus Inc.
- Survival Study Of Oncophage® vs. Observation In Patients With Kidney CancerCompletedNCT00033904Phase 3
- Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV MelanomaCompletedNCT00039000Phase 3
- Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell CarcinomaTerminatedNCT00082459Phase 2
- AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™TerminatedNCT00058747Phase 2
- Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney CancerTerminatedNCT00126178Phase 3
- Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung CancerCompletedNCT00098085Phase 2
- Trial Evaluating Safety, Tolerability and Immune Response of AG-707CompletedNCT00231049Phase 1
- Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell LymphomaCompletedNCT00316511Phase 1
- Aroplatin and Capecitabine in Patients With Advanced Colorectal Cancer Resistant to Standard TherapiesStatus unknownNCT00081536Phase 1/2
Sponsor listed in the registry: Aronex Pharmaceuticals · First submitted after Aronex Pharmaceuticals became part of Agenus Inc.
- Aroplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer Resistant to Standard TherapiesStatus unknownNCT00081549Phase 1/2
Sponsor listed in the registry: Aronex Pharmaceuticals · First submitted after Aronex Pharmaceuticals became part of Agenus Inc.
- A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid MalignanciesStatus unknownNCT00057395Phase 1/2
Sponsor listed in the registry: Aronex Pharmaceuticals · First submitted after Aronex Pharmaceuticals became part of Agenus Inc.
- A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Colorectal Cancer Resistant to Standard TherapiesStatus unknownNCT00043199Phase 2
Sponsor listed in the registry: Aronex Pharmaceuticals · First submitted after Aronex Pharmaceuticals became part of Agenus Inc.
- Safety and Effectiveness of Zintevir (AR177) Given to HIV-Infected PatientsCompletedNCT00002403Phase 1
Sponsor listed in the registry: Aronex Pharmaceuticals · First submitted before Aronex Pharmaceuticals became part of Agenus Inc.